Kalaris Therapeutics, Inc. (KLRS) stock
KLRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.28−0.07 (-5.19%)
Close on Nov 20, 2026Market cap $30.47MP/E –Yield –
Kalaris Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Kalaris Therapeutics's free cash flow for the twelve months ending Dec 31, 2025 was -$38.57M. For fiscal 2025 it was -$38.57M.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$38.57M | – |
| FY2021 | Dec 31, 2021 | -$106.35M | – |
| FY2020 | Dec 31, 2020 | -$61.05M | – |
| FY2019 | Dec 31, 2019 | -$20.49M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | -$7.07M | – |
| Q4 FY2021 | Dec 31, 2021 | -$27.70M | – |
| Q3 FY2021 | Sep 30, 2021 | -$36.47M | – |
| Q2 FY2021 | Jun 30, 2021 | -$23.18M | – |
| Q1 FY2021 | Mar 31, 2021 | -$19.00M | – |
| Q4 FY2019 | Dec 31, 2019 | -$8.99M | – |
| Q3 FY2019 | Sep 30, 2019 | -$6.40M | – |
See a number that looks wrong?